People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Pharmaceuticals, Other Health Care, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Zogenix Inc | — | Pharmaceuticals | Series C | $131.2M | $526.4M | 2010 |
| Elira, Inc. | — | Other Health Care | Seed | $14.0M | $21.5M | 2016 |
| Targegen Inc | — | Biotechnology | Seed | $3.7M | $165.6M | 2009 |
Arda M. Minocherhomjee at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Arda M. Minocherhomjee on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Cam L. Garner | 1 | 11 |
| James C. Blair | 1 | 8 |
| Ivor Royston | 1 | 7 |
| Louis C. Bock | 1 | 7 |
| Bevil J Hogg | 1 | 5 |
| Annette Bianchi | 1 | 4 |
| C. David Adair | 1 | 4 |
| Kurt C. Wheeler | 1 | 3 |
| Erle T. Mast | 1 | 3 |
| Alex Zisson | 1 | 3 |
| Raul E Perez | 1 | 3 |
| Andrew E. Senyei | 1 | 3 |
| David W. Nassif | 1 | 2 |
| Paul V. Goode | 1 | 2 |
| Phillip Schneider | 1 | 2 |
| Roger L. Hawley | 1 | 2 |
| Charles A. Bolten | 1 | 2 |
| Ralph G. Dacey | 1 | 2 |
| A. Travis Spitzer | 1 | 2 |
| Ken M. Haas | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.